Gastrointestinal (GI) symptoms generally include bloating, heartburn, indigestion/dyspepsia, and constipation. According to a new study, almost 74 percent of Americans suffer with digestive symptoms like gas, diarrhea, bloating and abdominal pain. In this study scope, gastrointestinal disease or disorder includes gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Among the considered conditions, incidence of GERD is the highest and commonly observed, followed by IBS and IBD. Thus rise in chronic gastrointestinal disorders and diseases, along with availability of OTC drugs are driving the growth of gastrointestinal drugs market.
The report titled Gastrointestinal Agents Market - Growth, Future Prospects and Competitive Analysis, 2022-2030 offers strategic insights into the overall gastrointestinal agents market along with the market size and estimates for the duration 2020 to 2030. The said research study covers in-depth analysis of multiple market segments based on type of drugs and different geographies. The drug types studied for analyzing the overall global gastrointestinal agents market are majorly segmented into antidiarrheal, anti-ulcers, laxatives, inflammatory bowel disease drugs and irritable bowel syndrome drugs
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global gastrointestinal agents market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global gastrointestinal agents market. This report concludes with company profiles section that highlights major information about the key players engaged in global gastrointestinal agents market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.
Medications for gastrointestinal diseases and symptoms include prescription and nonprescription drugs, conventional and unconventional agents, simple small molecules, complex macromolecules and large recombinant proteins. In base year 2016, the inflammatory bowel disease held the largest share in the gastrointestinal agents market due high prevalence of inflammatory bowel disease in the region. While, irritable bowel syndrome is anticipated to grow at the highest CAGR during the forecast period.
At present, North America dominates the global gastrointestinal agents market. Particularly U.S. captures the largest market share in the regional gastrointestinal agents market. However, the region is expected to witness flat growth due to maturity of this market and no anticipated competition from potential drug. Europe is considered to be the second largest gastrointestinal agents market. Asia Pacific is anticipated to be the fastest growing market in the forecast period. Rising incidence of gastrointestinal disease and disorder, advancement in technology and overall improvement in health care infrastructure in emerging economies are the key drivers for Asia Pacific market.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Gastrointestinal Agents market are as follows:
- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Gastrointestinal Agents market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Drug Class
- Antidiarrheal
- Anti-emetics
- Anticholinergic Agents
- Antihistamines
- Serotonin 5-HT3 Receptor Antagonists
- Cannabinoid Receptor Agonist
- Anti-ulcers
- Histamine type 2 receptor blockers (H2 blockers)
- Proton Pump Inhibitors
- Laxatives
- Inflammatory bowel disease
- 5-Aminosalicyclic Acid (5-ASA) Derivatives
- Immunosuppressive Agents
- Tumor Necrosis Factor Antagonists
- Irritable bowel syndrome
- Antimuscarinics/Antispasmodics
- Prokinetic Agents
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Gastrointestinal Agents market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Gastrointestinal Agents market?
- Which is the largest regional market for Gastrointestinal Agents market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Gastrointestinal Agents market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Gastrointestinal Agents market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Gastrointestinal Agents Market
2.2. Global Gastrointestinal Agents Market, By Drug Class, 2021 (US$ Million)
2.3. Global Gastrointestinal Agents Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021
3. Gastrointestinal Agents Market: Competitive Analysis
3.1. Market Positioning of Key Gastrointestinal Agents Market Vendors
3.2. Strategies Adopted by Gastrointestinal Agents Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Gastrointestinal Agents Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Gastrointestinal Agents Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Antidiarrheal
5.3.2. Anti-emetics
5.3.2.1. Anticholinergic Agents
5.3.2.2. Antihistamines
5.3.2.3. Serotonin 5-HT3 Receptor Antagonists
5.3.2.4. Cannabinoid Receptor Agonists
5.3.3. Anti-ulcers
5.3.3.1. Histamine type 2 receptor blockers (H2 blockers)
5.3.3.2. Proton Pump Inhibitors
5.3.4. Laxatives
5.3.5. Inflammatory bowel disease
5.3.5.1. 5-Aminosalicyclic Acid (5-ASA) Derivatives
5.3.5.2. Immunosuppressive Agents
5.3.5.3. Tumor Necrosis Factor Antagonists
5.3.6. Irritable bowel syndrome
5.3.6.1. Antimuscarinics/Antispasmodics
5.3.6.2. Prokinetic Agents
6. North America Gastrointestinal Agents Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
6.3.Gastrointestinal Agents Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
7. UK and European Union Gastrointestinal Agents Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
7.3.Gastrointestinal Agents Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
8. Asia Pacific Gastrointestinal Agents Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
8.3.Gastrointestinal Agents Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
9. Latin America Gastrointestinal Agents Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
9.3.Gastrointestinal Agents Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
10. Middle East and Africa Gastrointestinal Agents Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
10.3.Gastrointestinal Agents Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Gastrointestinal Agents Market: By Drug Class, 2020-2030, USD (Million)
11. Company Profile
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Allergan Plc. (Formerly Actavis Plc.)
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. AstraZeneca
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Bayer AG
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Boehringer Ingelheim GmbH
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. GlaxoSmithKline plc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Janssen Biotech, Inc.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Ranbaxy Laboratories Limited
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Sanofi
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Takeda Pharmaceutical
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Valeant Pharmaceuticals, Inc.
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
List of Figures
Figure 1 Global Gastrointestinal Agents Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Gastrointestinal Agents Market: Quality Assurance
Figure 5 Global Gastrointestinal Agents Market, By Drug Class, 2021
Figure 6 Global Gastrointestinal Agents Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Gastrointestinal Agents Market, 2021
Figure 8 Market Positioning of Key Gastrointestinal Agents Market Players, 2021
Figure 9 Global Gastrointestinal Agents Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Gastrointestinal Agents Market, By Drug Class, 2021 Vs 2030, %
Figure 11 U.S. Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 12 Canada Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 14 UK Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 15 Germany Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 16 Spain Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 17 Italy Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 18 France Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 20 China Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 21 Japan Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 22 India Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 23 Australia Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 24 South Korea Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 26 Brazil Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 27 Mexico Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 29 GCC Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 30 Africa Gastrointestinal Agents Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Gastrointestinal Agents Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 2 Global Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 3 Global Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 4 Global Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 5 Global Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 6 North America Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 7 North America Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 8 North America Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 9 North America Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 10 North America Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 11 U.S. Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 12 U.S. Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 13 U.S. Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 14 U.S. Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 15 U.S. Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 16 Canada Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 17 Canada Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 18 Canada Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 19 Canada Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 20 Canada Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 21 Rest of North America Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 22 Rest of North America Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 23 Rest of North America Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 24 Rest of North America Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 25 Rest of North America Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 26 UK and European Union Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 27 UK and European Union Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 28 UK and European Union Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 29 UK and European Union Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 30 UK and European Union Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 31 UK Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 32 UK Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 33 UK Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 34 UK Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 35 UK Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 36 Germany Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 37 Germany Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 38 Germany Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 39 Germany Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 40 Germany Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 41 Spain Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 42 Spain Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 43 Spain Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 44 Spain Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 45 Spain Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 46 Italy Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 47 Italy Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 48 Italy Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 49 Italy Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 50 Italy Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 51 France Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 52 France Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 53 France Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 54 France Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 55 France Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 56 Rest of Europe Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 57 Rest of Europe Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 58 Rest of Europe Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 59 Rest of Europe Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 60 Rest of Europe Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 61 Asia Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 62 Asia Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 63 Asia Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 64 Asia Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 65 Asia Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 66 China Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 67 China Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 68 China Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 69 China Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 70 China Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 71 Japan Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 72 Japan Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 73 Japan Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 74 Japan Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 75 Japan Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 76 India Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 77 India Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 78 India Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 79 India Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 80 India Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 81 Australia Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 82 Australia Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 83 Australia Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 84 Australia Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 85 Australia Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 86 South Korea Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 87 South Korea Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 88 South Korea Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 89 South Korea Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 90 South Korea Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 91 Latin America Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 92 Latin America Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 93 Latin America Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 94 Latin America Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 95 Latin America Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 96 Brazil Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 97 Brazil Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 98 Brazil Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 99 Brazil Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 100 Brazil Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 101 Mexico Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 102 Mexico Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 103 Mexico Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 104 Mexico Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 105 Mexico Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 106 Rest of Latin America Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 107 Rest of Latin America Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 108 Rest of Latin America Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 109 Rest of Latin America Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 110 Rest of Latin America Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 111 Middle East and Africa Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 112 Middle East and Africa Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 113 Middle East and Africa Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 114 Middle East and Africa Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 115 Middle East and Africa Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 116 GCC Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 117 GCC Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 118 GCC Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 119 GCC Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 120 GCC Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 121 Africa Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 122 Africa Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 123 Africa Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 124 Africa Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 125 Africa Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Table 126 Rest of Middle East and Africa Gastrointestinal Agents Market By Drug Class, 2020-2030, USD (Million)
Table 127 Rest of Middle East and Africa Gastrointestinal Agents Market By Anti-emetics, 2020-2030, USD (Million)
Table 128 Rest of Middle East and Africa Gastrointestinal Agents Market By Anti-ulcers, 2020-2030, USD (Million)
Table 129 Rest of Middle East and Africa Gastrointestinal Agents Market By Inflammatory bowel disease, 2020-2030, USD (Million)
Table 130 Rest of Middle East and Africa Gastrointestinal Agents Market By Irritable bowel syndrome, 2020-2030, USD (Million)
Companies Mentioned
- Abbott Laboratories
- Allergan Plc. (Formerly Actavis Plc.)
- AstraZeneca
- Bayer AG
- Boehringer Ingelheim GmbH
- GlaxoSmithKline plc.
- Janssen Biotech Inc.
- Ranbaxy Laboratories Limited
- Sanofi
- Takeda Pharmaceutical
- Valeant Pharmaceuticals Inc.
